Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
NCT03558503Phase 2Completed
- Sponsor
- UroGen Pharma
- Start
- Oct 2018
- Primary completion
- Jan 2020
- Modality
- DNA Intercalators/Alkylators, Hydrogel Systems
- Countries
- 2
01
Overview
A Phase 2 trial of zusduri in non-muscle-invasive bladder cancer (NMIBC), sponsored by UroGen Pharma. Started Oct 2018; status: completed.
02
Drugs
zusduri
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03558503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03558503.